Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Is a long-term, downside reversal in this sector, about to bubble to the surface?
With yesterday’s update, it’s easy to get lost in the hourly and daily maneuvers; see a likely (short-term) potential, while it just distracts from the bigger picture.
That ‘big picture’, is below.
Once again, we have a (potential) repeating set-up: Wyckoff ‘Spring-to-Up-Thrust.
Biotech XBI, Weekly Close
With this week’s volatile action but lower overall close (from last week), the ‘up-thrust test may be complete (not advice, not a recommendation).
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Do we have a ‘one-off’ event or is the data point being repeated?
To help answer, this site’s been monitoring what should be one of the fastest selling (used) cars in the market, Toyota Camry.
Scanning the CarMax inventory of Camry’s has the same cars (with minor changes) still for sale, since August, at elevated prices no -less.
Seems to corroborate the link above and makes you wonder what’s (really) happening?
With that, let’s move on to the potential opportunity.
CarMax KMX, Weekly
There’s a lot going on in this chart.”
“What do you see?”
The wedge is obvious.
Maybe a little more subtle until it’s pointed out, huge volume churn since the breakdown during the week of September 30th, 2022.
That’s over two-years of potential distribution.
From a Wyckoff standpoint using his ‘Cause and Effect’ analogy, whatever’s about to happen to KMX, it’s setting itself up for a potential, sustained, long-duration move (not advice, not a recommendation).
Earnings Release
Earnings scheduled for December 19th, before the open.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
The next trade (lower) could be in silver itself, or it could be in the Junior Miners, GDXJ, and/or SILJ, the sectors (ETFs) most susceptible (not advice, not a recommendation).
The last time silver had a major downswing was in early-to-late 2022; tracking fund SLV, declined about -35%, top-to-bottom.
During the same period, Junior Miners GDXJ, declined over -50%, so take your pick.
Silver SLV, closed out last week penetrating downside support and then moving (inching) back higher.
We should all know what that means. 🙂
Silver SLV, Weekly
Silver penetrates support and then retraces; Wyckoff ‘spring’ position (not advice, not a recommendation).
The 50% retrace area is shown. It will be interesting to see if SLV, gets that far.
Perhaps more interesting from a set-up standpoint, is what GDXJ, and SILJ, will be doing if and when that happens.
Positioning: SLV & Miners
The mining sector has been ‘out-of-favor’ since this update years ago.
Since that time and looking at the charts, the most dynamic (fastest action) trade opportunities, were to the downside.
There are no open positions in this sector at this time (not advice, not a recommendation).
Positioning: Biotech, XBI-24-01
Separately, as stated in this update, the short trade in biotech (via XBI) was brief.
It was stopped out with a loss of 0.15-pts (not advice, not a recommendation).
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.